Pressure UlcerNCT02348294
The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus
A study testing Shear- force 19 newton and 3,9 kpa pressure for half an hour in people with Pressure Ulcer and Diabetes Mellitus Type 2, run by Maastricht University Medical Center.
Trial summary
1. The objective of this study is to acquire knowledge about the development of reactive hyperaemia and inflammatory responses of the skin after shear- force and pressure loading. We want to investigate if patients with diabetes type 2 will develop more skin damage, because of a decreased microvascular function. 2. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Pressure Ulcer, Diabetes Mellitus Type 2, Charcot- Osteoarthropathy
- What is being tested?
- Shear- force 19 newton and 3,9 kpa pressure for half an hour
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- Feb 2015to Jan 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Group A:
- Healthy volunteers
- > 40 years
- Group B;
- patients with Diabetes Mellitus type 2 (DM) without neuropathy
- age > 40 years
Show all 15Show fewer
- Valk score < 4
- Group C:
- Patients with DM type 2 with neuropathy
- age > 40 years
- Valk score > 4
- Group D
- Patients with (pre)- existing Charcot Osteoarhtropathy
- age > 40 years
- Valk score > 4
Who cannot join
- Trauma fore arms
- Skin diseases (psoriasis, eczema)
- NSAID use in last seven days
- Bèta blocker use
- Corticosteroids
- Auto- immune diseases
Show all 11Show fewer
- Muscular dystrophy
- Malignancy
- Participant is unable to give informed consent
- Peripheral artery disease (doppler eai <0.9)
- Hab1c percentage last 3 months > 11%
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Measurement of Cytokines, Bloodflow and Erythema Index After Pressure and Shear- Force Loading in Patients With Diabetes Mellitus Type 2
- The objective of this study is to acquire knowledge about the development of reactive hyperaemia and inflammatory responses of the skin after shear- force and pressure loading. We want to investigate if patients with diabetes type 2 will develop more skin damage, because of a decreased microvascular function.
- The second objective of this study is: to investigate if the cytokine production of the skin is increased in patients with type 2 diabetes with a history of Charcot osteoarthropathy in comparison with patients with neuropathy without a history of Charcot osteoarthropathy.
The participant is asked to put his left arm on a support cushion. Then we mark an area of 2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we measure the cutaneous blood cell flux within the borders of the marked area with a Laser doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear- force for half an hour. After this period a new Sebutape is placed for two minutes, followed by cutaneous blood cell flux and the erythema index measurement within the borders of the marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60 minutes, At the same time we performed the same experiment at the right arm, but instead of loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm. The same measures with the sebutape, laser doppler and colorimeter are done before and after loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60 minutes.
Read the detailed description
- Pressure ulcers, also known as bedsores occurs as a result of mechanical loading (combination of pressure and shear- force) of the skin. We proved that IL-1alpha (measurement of skin damage) and reactive hyperaemia (RH) are increased after a combined loading of pressure and shear- force with our own developed shear- force model. This RH is probably a protective mechanism of the loaded skin and is clinically seen as blanchable erythema. Blanchable erythema is seen as an important risk indicator for the development of pressure ulcers. Patients with Diabetes Mellitus type 2, however, will develop less blanchable erythema (RH), because of a decreased micro vascular function. Therefore, they will get less preventive measures against pressure ulcers. We do expect, however, that more skin damage occurs when RH is decreased, so we want to investigate if patients with type 2 diabetes (with or without neuropathy) will develop less RH and more skin damage (IL-1alpha) after shear force application at the skin compared with healthy volunteers.
- Charcot- neuro- osteoarthropathy is a rare, but serious complication of polyneuropathy. Most of the times it occurs at the feet in patients with diabetes with neuropathy. It is associated with inflammation, hyperaemia, bone deformation and luxation of the joints. The pathogenesis is not well understood: the hyperemic response of the skin to external stimuli is increased, but we do not know if this hyperaemia is a result of primary hypervascularity or a increase in primary cytokines. Our research model gives us the opportunity to investigate if: the local cytokine production is increased in patients with diabetes type with neuropathy and a history of charcot osteoarthropathy after shear- force application at the skin compared with patients with type 2 diabetes with neuropathy.
Study population:
Group A:
- Healthy volunteers
- > 40 years
Group B;
- patients with Diabetes Mellitus type 2 (DM) without neuropathy
- age > 40 years
- Valk score < 4
Group C:
- Patients with DM type 2 with neuropathy
- age > 40 years
- Valk score > 4
Group D
- Patients with (pre)- existing Charcot Osteoarhtropathy
- age > 40 years
- Valk score > 4 Primary study parameters/outcome of the study
- IL-1 α/ total protein ratio
- Bloodflow of the skin (in flux )
- Erythema index of the skin
The participant is asked to put his left arm on a support cushion. Then we mark an area of 2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we measure the cutaneous blood cell flux within the borders of the marked area with a Laser doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear- force for half an hour. After this period a new Sebutape is placed for two minutes, followed by cutaneous blood cell flux and the erythema index measurement within the borders of the marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60 minutes, At the same time we performed the same experiment at the right arm, but instead of loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm. The same measures with the sebutape, laser doppler and colorimeter are done before and after loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60 minutes.
Outcomes; IL-1alpha/ total protein- ratio Cutaneous blood cell flux Erythema index
- Being tested
- Shear- force 19 newton and 3,9 kpa pressure for half an hour
- Medical subject headings
- Pressure Ulcer, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Shear- force 19 newton and 3,9 kpa pressure for half an hourOther
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | Other | Shear- force 19 newton and 3,9 kpa pressure for half an hour Receives: Other: Shear- force 19 newton and 3,9 kpa pressure for half an hour |
| Diabetes Mellitus type 2 without neuropathy | Other | Shear- force 19 newton and 3,9 kpa pressure for half an hour Receives: Other: Shear- force 19 newton and 3,9 kpa pressure for half an hour |
| Diabetes Mellitus type 2 with neuropathy | Other | Shear- force 19 newton and 3,9 kpa pressure for half an hour Receives: Other: Shear- force 19 newton and 3,9 kpa pressure for half an hour |
| Charcot Osteoarhtopathy | Other | Shear- force 19 newton and 3,9 kpa pressure for half an hour Receives: Other: Shear- force 19 newton and 3,9 kpa pressure for half an hour |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increase in IL-1alpha/ total protein ratio
Measured: 0, 15, 30, 45, 60 minutes after intervention
Increase in Cutaneous blood cell flux
Measured: 0, 15, 30, 45, 60 minutes after intervention
Increase in erythema index
Measured: 0, 15, 30, 45, 60 minutes after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2015 (estimated)
- Study startFeb 2015
- Primary completionJan 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pressure UlcerStudies of the same condition, open and under way.
- More trials run by Maastricht University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02348294
- Sponsor's protocol ID
- NL50794.068.14
- Status last verified
- Jan 2015
- First submitted
- 22 Jan 2015
- Last updated
- 28 Jan 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measurement of Cytokines, Bloodflow and Erythema Index After Pressure and Shear- Force Loading in Patients With Diabetes Mellitus Type 2
- ClinicalTrials.gov ID
- NCT02348294
- Acronym / sponsor ID
- NL50794.068.14
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Study start
- Feb 2015
- Primary completion
- Jan 2016 (estimated)
- First posted
- 28 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- The objective of this study is to acquire knowledge about the development of reactive hyperaemia and inflammatory responses of the skin after shear- force and pressure loading. We want to investigate if patients with diabetes type 2 will develop more skin damage, because of a decreased microvascular function.
- The second objective of this study is: to investigate if the cytokine production of the skin is increased in patients with type 2 diabetes with a history of Charcot osteoarthropathy in comparison with patients with neuropathy without a history of Charcot osteoarthropathy.
The participant is asked to put his left arm on a support cushion. Then we mark an area of 2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we measure the cutaneous blood cell flux within the borders of the marked area with a Laser doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear- force for half an hour. After this period a new Sebutape is placed for two minutes, followed by cutaneous blood cell flux and the erythema index measurement within the borders of the marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60 minutes, At the same time we performed the same experiment at the right arm, but instead of loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm. The same measures with the sebutape, laser doppler and colorimeter are done before and after loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60 minutes.
Detailed description
- Pressure ulcers, also known as bedsores occurs as a result of mechanical loading (combination of pressure and shear- force) of the skin. We proved that IL-1alpha (measurement of skin damage) and reactive hyperaemia (RH) are increased after a combined loading of pressure and shear- force with our own developed shear- force model. This RH is probably a protective mechanism of the loaded skin and is clinically seen as blanchable erythema. Blanchable erythema is seen as an important risk indicator for the development of pressure ulcers. Patients with Diabetes Mellitus type 2, however, will develop less blanchable erythema (RH), because of a decreased micro vascular function. Therefore, they will get less preventive measures against pressure ulcers. We do expect, however, that more skin damage occurs when RH is decreased, so we want to investigate if patients with type 2 diabetes (with or without neuropathy) will develop less RH and more skin damage (IL-1alpha) after shear force application at the skin compared with healthy volunteers.
- Charcot- neuro- osteoarthropathy is a rare, but serious complication of polyneuropathy. Most of the times it occurs at the feet in patients with diabetes with neuropathy. It is associated with inflammation, hyperaemia, bone deformation and luxation of the joints. The pathogenesis is not well understood: the hyperemic response of the skin to external stimuli is increased, but we do not know if this hyperaemia is a result of primary hypervascularity or a increase in primary cytokines. Our research model gives us the opportunity to investigate if: the local cytokine production is increased in patients with diabetes type with neuropathy and a history of charcot osteoarthropathy after shear- force application at the skin compared with patients with type 2 diabetes with neuropathy.
Study population:
Group A:
- Healthy volunteers
- > 40 years
Group B;
- patients with Diabetes Mellitus type 2 (DM) without neuropathy
- age > 40 years
- Valk score < 4
Group C:
- Patients with DM type 2 with neuropathy
- age > 40 years
- Valk score > 4
Group D
- Patients with (pre)- existing Charcot Osteoarhtropathy
- age > 40 years
- Valk score > 4 Primary study parameters/outcome of the study
- IL-1 α/ total protein ratio
- Bloodflow of the skin (in flux )
- Erythema index of the skin
The participant is asked to put his left arm on a support cushion. Then we mark an area of 2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we measure the cutaneous blood cell flux within the borders of the marked area with a Laser doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear- force for half an hour. After this period a new Sebutape is placed for two minutes, followed by cutaneous blood cell flux and the erythema index measurement within the borders of the marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60 minutes, At the same time we performed the same experiment at the right arm, but instead of loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm. The same measures with the sebutape, laser doppler and colorimeter are done before and after loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60 minutes.
Outcomes; IL-1alpha/ total protein- ratio Cutaneous blood cell flux Erythema index
Study design
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | Other | Other: Shear- force 19 newton and 3,9 kpa pressure for half an hourShear- force 19 newton and 3,9 kpa pressure for half an hour |
| Diabetes Mellitus type 2 without neuropathy | Other | Other: Shear- force 19 newton and 3,9 kpa pressure for half an hourShear- force 19 newton and 3,9 kpa pressure for half an hour |
| Diabetes Mellitus type 2 with neuropathy | Other | Other: Shear- force 19 newton and 3,9 kpa pressure for half an hourShear- force 19 newton and 3,9 kpa pressure for half an hour |
| Charcot Osteoarhtopathy | Other | Other: Shear- force 19 newton and 3,9 kpa pressure for half an hourShear- force 19 newton and 3,9 kpa pressure for half an hour |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Group A:
- Healthy volunteers
- > 40 years
- Group B;
- patients with Diabetes Mellitus type 2 (DM) without neuropathy
Key exclusion criteria (11 listed)
- Trauma fore arms
- Skin diseases (psoriasis, eczema)
- NSAID use in last seven days
- Bèta blocker use
- Corticosteroids
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Shear- force 19 newton and 3,9 kpa pressure for half an hour | Other | Charcot Osteoarhtopathy, Diabetes Mellitus type 2 with neuropathy, Diabetes Mellitus type 2 without neuropathy, Healthy volunteers |
Primary outcome
Increase in IL-1alpha/ total protein ratio
Time frame: 0, 15, 30, 45, 60 minutes after intervention
Increase in Cutaneous blood cell flux
Time frame: 0, 15, 30, 45, 60 minutes after intervention
Increase in erythema index
Time frame: 0, 15, 30, 45, 60 minutes after intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2015.
Related trials for Pressure Ulcer
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Not yet recruiting
Pulsed High Intensity Laser Versus Negative Pressure Therapy On Neuropathic Ulcers
Neuropathic Ulcers
Recruiting
Efficacy and Safety of ZKARE® Gel and Its Accessory ZKAPI® in the Treatment of Chronic Ulcers.
Chronic Ulcers
Not yet recruiting
The Effectiveness of a Caregiver-Based Multicomponent Intervention to Prevent Pressure Ulcers in Home-Cared-For Individuals With Dementia
Dementia, Home Care for Elderly or Disabled Individuals
Not yet recruitingObservational study
Hypertrophic Scar Prosthetic Pressure in Burn Amputee
Amputation Stump, Burn Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A study testing Shear- force 19 newton and 3,9 kpa pressure for half an hour in people with Pressure Ulcer and Diabetes Mellitus Type 2, run by Maastricht University Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Luuk de Wert, MD (+31618074833, luuk.wertde@mumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increase in IL-1alpha/ total protein ratio (time frame: 0, 15, 30, 45, 60 minutes after intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2015.